Decitabine-based treatment strategy improved the outcome of HSCT in JMML: a retrospective cohort study
Implementing a DAC-based administration strategy throughout the pre-HSCT period, during HSCT regimens, and in post-HSCT maintenance significantly reduced relapse and improved survival in JMML patients. Both DAC monotherapy and the DAC plus FLAG protocol proved effective as pre-HSCT treatments.
Authors
- Haoran Tang (ORCID: https://orcid.org/0000-0002-0963-7230)
- Jingyu Gao
- Zhiyong Peng (ORCID: https://orcid.org/0000-0002-3873-9607)
- Chunfu Li (ORCID: https://orcid.org/0000-0003-1858-2320)
- Xuan Liu (ORCID: https://orcid.org/0000-0001-5325-0685)
- Fuyu Pei (ORCID: https://orcid.org/0009-0008-8409-9189)
- Dan Yue (ORCID: https://orcid.org/0009-0002-7107-0471)
- Litao Huang
- Sa Zong
- Xuedong Wu (ORCID: https://orcid.org/0009-0001-7612-1429)
- Yue Li (ORCID: https://orcid.org/0000-0003-4547-064X)
- Chen Chen (ORCID: https://orcid.org/0000-0003-2104-534X)
- Xia Li (ORCID: https://orcid.org/0000-0002-9794-2648)
- Xiaoqin Feng (ORCID: https://orcid.org/0000-0003-1166-0138)
- Jun Zhou (ORCID: https://orcid.org/0000-0002-5895-2472)
- Yanru Pei (ORCID: https://orcid.org/0000-0001-6036-1498)
- Yun Chen (ORCID: https://orcid.org/0009-0004-7275-6525)
- Jing Ge
- Yuelin He
Institutions
- Sun Yat-sen University (CN)
- The Seventh Affiliated Hospital of Sun Yat-sen University (CN)
- Nanfang Hospital (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-08-26
- DOI
- https://doi.org/10.3389/fimmu.2024.1426640
- Citations
- 4
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 1.75
Funders
- National Natural Science Foundation of China
- Nanfang Hospital